ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 32364
Title: Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis
Reviewer’s code: 03700072
Reviewer’s country: Turkey
Science editor: Jing Yu
Date sent for review: 2017-01-07 08:14
Date reviewed: 2017-01-15 19:39

CLASSIFICATION
[ ] Grade A: Excellent
[ Y] Grade B: Very good
[ ] Grade C: Good
[ ] Grade D: Fair
[ ] Grade E: Poor

LANGUAGE EVALUATION
[ Y] Grade A: Priority publishing
[ ] Grade B: Minor language polishing
[ ] Grade C: A great deal of language polishing
[ ] Grade D: Rejected

SCIENTIFIC MISCONDUCT
Google Search:
[ ] The same title
[ ] Duplicate publication
BPG Search:
[ Y] No

CONCLUSION
[ Y] Accept
[ ] High priority for publication
[ ] Rejection
[ ] Minor revision
[ ] Major revision

COMMENTS TO AUTHORS
Overall, this is a clear and well-written manuscript. The introduction is relevant and theory based. The methods are appropriate and the results are clear. The authors make a contribution to the research literature in this area of investigation.
ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 32364
Title: Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis
Reviewer’s code: 03699892
Reviewer’s country: United States
Science editor: Jing Yu
Date sent for review: 2017-01-07 08:14
Date reviewed: 2017-01-16 06:01

CLASSIFICATION
[ ] Grade A: Excellent
[ ] Grade B: Very good
[ Y] Grade C: Good
[ ] Grade D: Fair
[ ] Grade E: Poor

LANGUAGE EVALUATION
[ Y] Grade A: Priority publishing
[ ] Grade B: Minor language polishing
[ ] Grade C: A great deal of language polishing
[ ] Grade D: Rejected

SCIENTIFIC MISCONDUCT
Google Search:
[ ] The same title
[ ] Duplicate publication
[ ] Plagiarism
BPG Search:
[ Y] No

CONCLUSION
[ Y] Accept
[ ] High priority for publication
[ ] Rejection
[ ] Minor revision
[ ] Major revision

COMMENTS TO AUTHORS
This is a nice retrospective study that reassures physicians with regard to the efficacy and renal safety of TDF in (Korean) patients with HBV-related cirrhosis. I have a few questions and comments - 1. Were there any decompensation events in either of the groups during the duration of the study? 2. Of the few patients who had a documented drop in GFR, did any have identifiable renal risk factors such as hypertension, diabetes, bacterial infections, or concomitant use of nephrotoxic medications? 3. Was Fanconi syndrome ruled out in patients with significant renal dysfunction on treatment? 4. on line 10 of the Result Section, the authors state that "The decompensated group had lower CTP and MELD scores" - it should state "higher".
ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 32364
Title: Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis
Reviewer's code: 02438878
Reviewer’s country: China
Science editor: Jing Yu
Date sent for review: 2017-01-07 08:14
Date reviewed: 2017-01-20 20:02

CLASSIFICATION | LANGUAGE EVALUATION | SCIENTIFIC MISCONDUCT | CONCLUSION
--- | --- | --- | ---
[ Y] Grade B: Very good | [ ] Grade B: Minor language polishing | [ ] Duplicate publication | [ ] High priority for publication
[ ] Grade C: Good | [ ] Grade C: A great deal of language polishing | [ Y ] No | [ ] Rejection
[ ] Grade D: Fair | [ ] Grade D: Rejected | [ ] Plagiarism | [ ] Minor revision
[ ] Grade E: Poor | | | [ ] Major revision

Google Search: [ ] The same title
BPG Search: [ ] The same title

COMMENTS TO AUTHORS
The study investigated the Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis and compared with compensated cirrhosis. The paper was well-written with good design and appropriate statistic method. But there are several limitations. 1. This is a retrospective study. 2. The case number is small. 3. Besides the tenofovir, the author should describe if the patients have taken any other treatments during follow-up period.
ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 32364
Title: Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis
Reviewer’s code: 03021970
Reviewer’s country: China
Science editor: Jing Yu
Date sent for review: 2017-01-07 08:14
Date reviewed: 2017-01-21 06:51

<table>
<thead>
<tr>
<th>CLASSIFICATION</th>
<th>LANGUAGE EVALUATION</th>
<th>SCIENTIFIC MISCONDUCT</th>
<th>CONCLUSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>[ ] Grade A: Excellent</td>
<td>[ Y] Grade A: Priority publishing</td>
<td>[ ] The same title</td>
<td>[ ] Accept</td>
</tr>
<tr>
<td>[ ] Grade B: Very good</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Duplicate publication</td>
<td>[ ] High priority for publication</td>
</tr>
<tr>
<td>[ Y] Grade C: Good</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Plagiarism</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade D: Rejected</td>
<td>[ Y] No</td>
<td>[ Y] Minor revision</td>
</tr>
<tr>
<td>[ ] Grade E: Poor</td>
<td></td>
<td>BPG Search:</td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>

COMMENTS TO AUTHORS
In the present manuscript the authors illustrated focus on when to treat, when to monitor, what patients should receive HBV therapy, and what drugs should be selected in HBV reactivations in cases of iatrogenic or natural IS. Although the information has been shown in some articles, the new developments in recent years are still not systemically reviewed. However, the article needs some minor correction before being published. Major concerns: 1. Patients disposition: as for all retrospective studies, a patient disposition figure is mandatory. How many treatment-naïve patients with CHB-related cirrhosis were diagnosed between January 2013 to January 2014 and how many patients were on oral therapy and discontinued treatment. Or how many patients stopped oral therapy between 2013 and 2014? 2. The upper limit of normal of ALT is defined as 40 IU/L in the present manuscript whatever the patient is male or female. But I suggest ULN of ALT is defined as 30 IU/L and 19 IU/L for male and female. 3. There are some spelling and grammar mistakes need to be corrected before being published.
ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 32364
Title: Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis
Reviewer's code: 03538176
Reviewer’s country: Yemen
Science editor: Jing Yu
Date sent for review: 2017-01-07 08:14
Date reviewed: 2017-01-22 10:09

<table>
<thead>
<tr>
<th>CLASSIFICATION</th>
<th>LANGUAGE EVALUATION</th>
<th>SCIENTIFIC MISCONDUCT</th>
<th>CONCLUSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>[ ] Grade A: Excellent</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[ ] The same title</td>
<td>[ ] Accept</td>
</tr>
<tr>
<td>[ ] Grade B: Very good</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Duplicate publication</td>
<td>[ ] High priority for publication</td>
</tr>
<tr>
<td>[ Y] Grade D: Fair</td>
<td>[ ] Grade D: Rejected</td>
<td>[ Y] No</td>
<td>[ ] Minor revision</td>
</tr>
<tr>
<td>[ ] Grade E: Poor</td>
<td></td>
<td></td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>

Google Search: [ ] The same title
BPG Search: [ ] The same title

COMMENTS TO AUTHORS
1 Suggestion to express accurately: such as: “The 1-year complete virological response (CVR) and Hepatitis B e Antigen (HBeAg) seroconversion were seen in 70.2% (40/57) and 14.2% (14/28), respectively” in the Abstract should be described as “The 1-year complete virological response (CVR) and Hepatitis B e Antigen (HBeAg) seroconversion were seen in 70.2% and 14.2% in the decompensated cirrhosis group, respectively” more relevantly. “Chronic hepatitis B (CHB) infection” on the first line should be revised “Chronic hepatitis B virus (HBV) infection” better. The unit of measurement of “Albumin” in the Table 1 should be expressed. In title “Virological, biochemical and serological and responses”, the word “and” should be removed. 2 The confounders of logistic regression analyses are not very appropriate. 3 Please revise your paper carefully before submitting.